Impact Therap-b (7630)의 가격은 얼마입니까?

Impact Therap-b (7630)의 가격은 $1.85입니다.

Impact Therap-b (7630)의 시가 총액은 무엇입니까?

Impact Therap-b (7630)의 시가 총액은 $510.85M입니다.

Impact Therap-b (7630) PER

IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.

연도	P/E 비율	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

P/E 비율

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	P/E 비율	P/E 비율 차이	국가
Eli Lilly and Company LLY.US	39.54	-	US
Johnson & Johnson JNJ.US	30.10	-	US
AbbVie Inc. ABBV.US	70.28	-	US
Roche Holding AG RO.SW	22.25	-	CH
Merck & Co., Inc. MRK.US	107.81	-	US

회사

P/E 비율

P/E 비율 차이

국가